Eden BioSolutions PLC (LSE:EDEN) has a new name and a fresh regulatory win to go with it. The AIM-quoted biopesticide developer announced a change of name to Eden BioSolutions PLC at the end of September 2026, and on 28 September the United States Environmental Protection Agency approved an expanded label for its Mevalone product. The company has since presented to investors and sent its commercial team to an industry gathering.

What the company does

The company develops and commercialises natural biocontrol products for agriculture, based on plant-derived active ingredients. Its Mevalone fungicide is its best-known product, and it has been extending it through new crops, diseases and countries. Related products include Novellus+, an enhanced version of Mevalone, Ecovelex, and Cedroz, which is registered on two continents and being taken further by Eastman Chemical.

Name change and latest news

The change of name was announced on 30 September 2026, following an announcement on 29 September, and republished on 1 October. On 6 October LSE:EDEN presented the same investor presentation it had previously given on its platform, and on 19 October it said members of its commercial team, including chief executive Sean Smith, would attend the annual biocontrol industry meeting. The US label expansion on 28 September followed regulatory approvals in Slovakia and Egypt, reported on 4 August.

Other corporate items in the period included the Annual General Meeting on 29 September, with all results published that day, and a grant of long-term incentive awards to directors and managers on 17 September.

Results

Preliminary results published on 26 August 2026 covered a 15-month period to 31 March 2026, after LSE:EDEN moved its year end from December, so the comparison with calendar 2024 is not like for like. Revenue was 4.85 million pounds against 4.30 million, Gross Profit was 2.23 million pounds against 1.87 million, and the operating loss widened to 2.86 million pounds from 2.19 million. Loss after tax was 2.45 million pounds, or 0.45 pence per share, against a loss of 1.91 million pounds in 2024. A data access agreement with associate company TerpeneTech, which supports its geraniol supplier status under European biocides rules, carries a fee of 0.4 million pounds. Cash at the period end was 1.52 million pounds, and net Assets were 12.43 million pounds.

Around the year end the company raised 10.8 million pounds gross, of which 7.6 million pounds arrived after the period end. The money is partly funding field trials in 2026 for late blight and septoria.

Commercial progress

Mevalone has been approved in California for powdery mildew on grapes and in France for downy and powdery mildew on grapes, where Corteva distributes it, while Italy approved new crops and diseases. Novellus+ was approved in Chile. Ecovelex received temporary approval in Italy for the 2026 maize season, with full European Union authorisation pending. Syngenta distributes for ornamentals in several European countries and the United Kingdom, and Andermatt Kenya is the exclusive Mevalone distributor in Kenya. A thymol Supply agreement with Veto-pharma covers bee-health use in the United States, and negotiations with two lead candidates for its insecticide are expected to reach agreement by the end of 2026.

Risks

The board's full-year expectations are unchanged but depend on variables such as Mevalone stocking for the 2027 season and potential upside on Ecovelex. Hot, dry weather in Europe and the United States could reduce use of Mevalone, and distributors may carry more unsold stock into the next season.

What to watch next

LSE:EDEN said it would update the market on season-end sales later in the year, and investors will follow EU authorisation of Ecovelex, any insecticide agreement and the effect of the new name on its branding.